Market News / Story
Lantern Pharma Inc. (LTRN) Wins Taiwan OK to Open Part 2 of LP-300 Phase 2 Trial
·
Lantern Pharma received TFDA and IRB approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300 in never-smoker, EGFR L858R NSCLC, increasing dosing eligibility to up to eight cycles. U.S. central IRB approval is in place and sites are identifying patients. Material Details #DetailAI Analyst View1TFDA and IRB approvals in TaiwanRegulatory greenlight enables near-term enrollment and data generation in a high-prevalence market.2Part 2 of Phase 2 HARMONIC…